Table 6.
Immunohistochemical findings for mTOR and p-mTOR in mouse model liver tumors and human HCCs.
| Subjects- | mTOR | p-mTOR | ||||||
|---|---|---|---|---|---|---|---|---|
| score 3+ | score 2+ | score 1+ | score 0 | score 3+ | score 2+ | score 1+ | score 0 | |
| Mouse models | ||||||||
| Liver tumors in TSOD mice | 39 (95%) | 0 (0%) | 0 (0%) | 2 (5%) | 20 (49%) | 3 (7%) | 13 (32%) | 5 (12%) |
| Liver tumors in CDAHFD-fed mice | 33 (94%) | 1 (3%) | 1 (3%) | 0 (0%) | 1 (3%) | 1 (3%) | 23 (66%) | 10 (28%) |
| Liver tumors in mice given DEN and PB | 84 (89%) | 7 (8%) | 3 (3%) | 0 (0%) | 1 (1%) | 5 (5%) | 54 (58%) | 34 (36%) |
| Human HCCs | ||||||||
| Metabolic syndrome/NASH-associated HCCs | 30 (65%) | 7 (15%) | 9 (20%) | 0 (0%) | 29 (63%) | 6 (13%) | 11 (23%) | 0 (0%) |
| virus-associated HCCs | 18 (58%) | 2 (7%) | 1135 (%) | 0 (0%) | 2 (7%) | 3 (10%) | 18 (58%) | 8 (25%) |
Score 0, negative staining; score 1+, positive staining in <25%; score 2+, positive staining in 25–50%; score 3+, positive staining in >50% of cells in the particular area. Data are numbers of positively stained liver tumors (Incidence (%)).